Business
Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category
Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of insomnia disorder, has been awarded the inaugural Prix Galien Bridges Award in the category of “Best Biotechnology & Pharmaceutical Product”Inaugural winners are honored for breakthrough innovations in life sciences Allschwil, Switzerland – December 9, 2025Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of insomnia disorder, has been awarded the inaugural Prix Galien Bridges Award in the category of “Best Biotechnology & Pharmaceutical Product”","length":263,"tagName":"p"}]},{"val":[{"type":"text","content":"Inaugural winners are honored for breakthrough innovations in life sciences","length":75,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":338,"olType":false},{"type":"text","content":"Allschwil, Switzerland – December 9, 2025Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien Bridges Award in the category of “Best Biotechnology & Pharmaceutical Product”. The award recognizes groundbreaking medicines, including biologics, gene therapies, and traditional pharmaceutical compounds, that advance patient care through scientific innovation.","length":432,"tagName":"p"},{"type":"text","content":"Bettina Blosse, General Manager of Idorsia Nordics, commented:"We are immensely proud to have been awarded the prestigious Prix Galien, particularly the first of its kind in the Nordics. The recognition from the jury is a wonderful endorsement of Idorsia's commitment to innovation in healthcare and the value that the new treatment brings to improving patient care for insomnia disorder. My team is working to make this medicine accessible to all patients in the Nordic region.”","length":489,"tagName":"p"},{"type":"text","content":"Martine Clozel, MD and Chief Scientific Officer added:“Our research team began work on the science of orexin and orexin receptors immediately after they were first described in 1998. Our initial work led to the understanding that antag...